Back to top
more

Kintara Therapeutics (KTRA)

(Delayed Data from NSDQ)

$0.21 USD

0.21
4,551,927

-0.05 (-18.11%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $0.21 0.00 (-0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for KTRA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Kintara Therapeutics, Inc. [KTRA]

Reports for Purchase

Showing records 21 - 40 ( 49 total )

Company: Kintara Therapeutics, Inc.

Industry: Medical - Drugs

Record: 21

04/12/2022

Company Report

Pages: 5

BUY: Raises Capital - $8.6M Gross; Dilution Lowers Our Price Target - Falls from $5.0 to $3.0

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Kintara Therapeutics, Inc.

Industry: Medical - Drugs

Record: 22

03/18/2022

Company Report

Pages: 5

BUY: Data Presentations at AACR

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Kintara Therapeutics, Inc.

Industry: Medical - Drugs

Record: 23

02/15/2022

Company Report

Pages: 5

Kintara Provides F2Q 2022 Earnings and Corporate Update; VAL-083 in Pivotal GBM AGILE Trial On Track for 2023 Readout

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: Kintara Therapeutics, Inc.

Industry: Medical - Drugs

Record: 24

02/14/2022

Company Report

Pages: 5

BUY: Fiscal Year 2022 Results - GCAR Enrollment is Strong

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Kintara Therapeutics, Inc.

Industry: Medical - Drugs

Record: 25

02/03/2022

Daily Note

Pages: 3

Issuance of US Patent Points to Potential Opportunities for VAL-083 Beyond GBM

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: Kintara Therapeutics, Inc.

Industry: Medical - Drugs

Record: 26

02/01/2022

Daily Note

Pages: 5

Comparison of Phase 2 Data in Newly Diagnosed GBM Patients Points to VAL-083 Efficacy Advantage

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: Kintara Therapeutics, Inc.

Industry: Medical - Drugs

Record: 27

01/19/2022

Company Report

Pages: 6

Kintara Pushes Back GBM-AGILE Readout to Year End 2023; Reiterate Buy, Lowering PT to $3

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 12.50

Research Provided by a Third Party

Company: Kintara Therapeutics, Inc.

Industry: Medical - Drugs

Record: 28

01/19/2022

Company Report

Pages: 5

BUY: GCAR - Enrollment / Timeline Update

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Kintara Therapeutics, Inc.

Industry: Medical - Drugs

Record: 29

01/13/2022

Daily Note

Pages: 4

Grant Awarded by Luxembourg Funding Agency for Research Into VAL-083 Mechanism of Action

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: Kintara Therapeutics, Inc.

Industry: Medical - Drugs

Record: 30

12/02/2021

Company Report

Pages: 5

BUY: GCAR Goes International First Site Activated

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Kintara Therapeutics, Inc.

Industry: Medical - Drugs

Record: 31

11/30/2021

Daily Note

Pages: 3

Kintara Announces Activation of First International Site for GBM-AGILE Trial in GBM; Joins 30 Active US Sites

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: Kintara Therapeutics, Inc.

Industry: Medical - Drugs

Record: 32

11/18/2021

Daily Note

Pages: 6

Kintara Presents Encouraging Phase 2 Results;Separate Pivotal Trial, GBM-AGILE on Track

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 12.50

Research Provided by a Third Party

Company: Kintara Therapeutics, Inc.

Industry: Medical - Drugs

Record: 33

11/16/2021

Company Report

Pages: 5

Kintara Reports 1Q2022; Recalibrated Leadership

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: Kintara Therapeutics, Inc.

Industry: Medical - Drugs

Record: 34

11/10/2021

Daily Note

Pages: 5

Leadership Change at Kintara is Conducive to Deal-Making and Execution.

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: Kintara Therapeutics, Inc.

Industry: Medical - Drugs

Record: 35

09/28/2021

Company Report

Pages: 31

Initiating coverage with a Buy rating and 12-month price target of $6

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 75.00

Research Provided by a Third Party

Company: Kintara Therapeutics, Inc.

Industry: Medical - Drugs

Record: 36

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for KTRA

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Kintara Therapeutics, Inc.

Industry: Medical - Drugs

Record: 37

09/22/2021

Company Report

Pages: 5

BUY: VAL-083 P2 Shows Promise in Newly Diagnosed GBM

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Kintara Therapeutics, Inc.

Industry: Medical - Drugs

Record: 38

09/09/2021

Company Report

Pages: 7

BUY: Two Pivotal Assets - REM-001 & VAL-083

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Kintara Therapeutics, Inc.

Industry: Medical - Drugs

Record: 39

08/17/2021

Company Report

Pages: 6

BUY: GCAR Update - 26 Sites Enrolling Now

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Kintara Therapeutics, Inc.

Industry: Medical - Drugs

Record: 40

07/01/2021

Company Report

Pages: 6

BUY: Phase 2 Results - VAL-083 in Recurrent GBM

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party